Signaling Pathways as Biomarkers

Sahasrabuddhe, Anagh A.; Rolland, Delphine C.M.; Banerjee, Pinaki P.

doi:10.4137/bic.s37778

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The uncontrolled signaling processes triggered the pathogenesis of various malignancies. , However, the characteristics and degrees to which these uncontrolled signaling processes affect certain families of malignancy are not completely known. Identifying signaling abnormalities related to specific malignancies can be used as cancer biomarkers . Information on oncogenes, associated with the vital cellular activities of GBM cells to form, proliferate, and endure, provides prospective analytical tools for the identification of GBM. , For example, treatment modalities can be selected based on accurate observation of GBM mutational status, genomic heterogeneity, and the oncogenic metabolism allied to fatty acid, glucose, hypoxia, and amino acid in GBM. − Notable changes in the amino acid levels have been observed via clinical radioisotope visualization: increased concentration of glutamine (Gln), glutamate (Glu), and methionine (Met), as well as decreased aspartate (Asp) levels .…”

Section: Biomarker-responsive Probesmentioning

confidence: 99%

“…Identifying signaling abnormalities related to specific malignancies can be used as cancer biomarkers. 100 Information on oncogenes, associated with the vital cellular activities of GBM cells to form, proliferate, and endure, provides prospective analytical tools for the identification of GBM. 101,102 For example, treatment modalities can be selected based on accurate observation of GBM mutational status, genomic heterogeneity, and the oncogenic metabolism allied to fatty acid, glucose, hypoxia, and amino acid in GBM.…”

Section: ■ Dye-encapsulated Probesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Progress in Fluorescent Probes for Real-Time Monitoring of Glioblastoma

Mondal

Kang

Kim

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Treating glioblastoma (GBM) by resecting to a large extent can prolong a patient's survival by controlling the tumor cells, but excessive resection may produce postoperative complications by perturbing the brain structures. Therefore, various imaging procedures have been employed to successfully diagnose and resect with utmost caution and to protect vital structural or functional features. Fluorescence tagging is generally used as an intraoperative imaging technique in glioma cells in collaboration with other surgical tools such as MRI and navigation methods. However, the existing fluorescent probes may have several limitations, including poor selectivity, less photostability, false signals, and intraoperative readministration when used in clinical and preclinical studies for glioma surgery. The involvement of smart fluorogenic materials, specifically fluorescent dyes, and biomarker-amended cellpenetrable fluorescent probes have noteworthy advantages for precise glioma imaging. This review outlines the contemporary advancements of fluorescent probes for imaging glioma cells along with their challenges and visions, with the anticipation to develop next-generation smart glioblastoma detection modalities.

show abstract